Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix (263855) in Pregnant Women

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix (263855) in Pregnant Women

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 05 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Planned End Date changed from 27 Dec 2017 to 20 Oct 2017.
    • 06 Jun 2017 Planned primary completion date changed from 13 Oct 2017 to 21 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top